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Abstract
Background: HOXA1 is a member of the Homeobox gene family, which encodes a group of highly conserved
transcription factors that are important in embryonic development. However, it has been reported that HOXA1
exhibits oncogenic properties in many malignancies. This study focused on the expression and clinical significance
of HOXA1 in gastric cancer (GC).
Methods: To assess the mRNA and protein expression of HOXA1 and cyclin D1 in GC tissues, we utilized qRT-PCR
and western blotting, respectively. The effects of HOXA1 on GC cell proliferation, migration, and invasion, as well as
xenograft tumor formation and the cell cycle were investigated in our established stable HOXA1 knockdown GC
cell lines. The protein expression of HOXA1 and cyclin D1 was examined by immunohistochemistry using GC tissue
microarrays (TMA) to analyze their relationship on a histological level. The Kaplan-Meier method and cox proportional
hazards model were used to analyze the relationship of HOXA1 and cyclin D1 expression with GC clinical outcomes.
Results: HOXA1 mRNA and protein expression were upregulated in GC tissues. Knockdown of HOXA1 in GC cells not
only inhibited cell proliferation, migration, and invasion in vitro but also suppressed xenograft tumor formation in vivo.
Moreover, HOXA1 knockdown induced changes in the cell cycle, and HOXA1 knockdown cells were arrested at the G1
phase, the number of cells in S phase was reduced, and the expression of cyclin D1 was decreased. In GC tissues, high
cyclin D1 mRNA and protein expression were detected, and a significant correlation was found between the expression
of HOXA1 and cyclin D1. Survival analysis indicated that HOXA1 and cyclin D1 expression were significantly associated
with disease-free survival (DFS) and overall survival (OS). Interestingly, patients with tumors that were positive for HOXA1
and cyclin D1 expression showed worse prognosis. Multivariate analysis confirmed that the combination of HOXA1 and
cyclin D1 was an independent prognostic indicator for OS and DFS.
Conclusion: Our data show that HOXA1 plays a crucial role in GC development and clinical prognosis. HOXA1, alone or
combination with cyclin D1, may serve as a novel prognostic biomarker for GC.
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Background
Gastric cancer (GC) is a leading cause of cancer-related
death worldwide [1, 2], and it is also the third most
common cancer and a major cause of cancer-related
death in China [3]. Although much progress has been
made in the diagnosis and treatment of GC in recent
years, the survival rate remains unsatisfactory (20–25 %)
[4], which may be attributable in part to late diagnosis
and the postoperative recurrence or metastasis of
primary GC. There are no distinct symptoms of GC, and
the current tumor markers are of little use for prognos-
tic evaluation [5, 6]. Thus, the identification of new
useful biomarkers for early detection and prognosis in
patients with GC is of great importance.
HOX genes, which were first discovered in Drosophila
melanogaster mutants in the early 1900s, constitute a
highly conserved subgroup of the homeobox superfamily
that encodes transcription factors with a 60-amino acid
domain called the homeodomain. HOX genes play
important roles in embryonic development by regulating
numerous processes, including cell proliferation, apop-
tosis, differentiation, angiogenesis, and so on [7–9]. In
mammals, there are 39 HOX genes, which are located in
4 chromosomal clusters, referred to as HOXA, B, C, and
D, that each contain 9–11 genes [9]. During normal
vertebrate development, HOX genes play an important
role in the mechanisms underlying the following three
basic precepts: spatial collinearity, posterior prevalence,
and temporal collinearity [8]. However, aberrant expres-
sion of HOX genes occurs in many cancers, such as
acute leukemia, lung cancer, and cervical carcinoma,
among others [10–14].
In our previous studies, we detected several differentially
expressed HOX genes in GC using high-throughput
cDNA microarrays [15]. Among these genes, HOXA1 was
more highly expressed in 8 out of 12 tumor tissues than in
normal tissues[15]. HOXA1 is a part of the A cluster on
chromosome 7, and it encodes a DNA binding
transcription factor that regulates the expression of genes
involved in morphogenesis, cell proliferation, and differen-
tiation [16–18]. Some studies have demonstrated the roles
that HOXA1 plays in tumorigenesis. Brock et al. [19]
showed that HOXA1 is a critical mediator of mammary
tumor progression in humans. A recent study showed that
loss of HOXA1 impairs cellular progression by blocking
the G1-S transition in HeLa cells [20]. In addition, Zhang
et al. [21] demonstrated that ectopic expression of
HOXA1 in MCF7 breast cancer cells upregulates cyclin
D1. Interestingly, cyclin D1 has been found to be highly
expressed in GC [22, 23] and many other malignancies
such as breast cancer [24] and cutaneous melanoma [25].
Cyclin D1 is well known for its role in the response to the
mitogenic signals that promote progression through the
G1-S checkpoint of the cell cycle [26]. Recently Seo et al.
[27] reported that downregulation of cyclin D1 in GC cells
by a lentivirus significantly inhibited cell function and
motility in vitro, and significantly inhibited cancer growth
when engrafted into nude mice. However, the relationship
between HOXA1 and cyclin D1 in GC has not been eluci-
dated in detail.
The current study aimed to investigate the expression
and clinical significance of HOXA1 in GC. First, we
assessed the expression of HOXA1 in GC at both the
transcriptional and translational levels. Second, we studied
the effects of HOXA1 on GC cell proliferation, migration,
invasion, cell cycle progression, and xenograft tumor
formation by knocking down the expression of HOXA1,
and we found that the expression of cyclin D1 was also
decreased. Third, we determined the mRNA and protein
expression of cyclin D1 in GC to examine the relationship
between HOXA1 and cyclin D1. Finally, we investigated
the relationship of HOXA1 and cyclin D1 with clinical
characteristics and the prognostic value of HOXA1, either
alone or in combination with cyclin D1, using GC tissue
microarrays (TMA). We found that HOXA1 plays a role
in the development and clinical prognosis of GC, and it
may be useful as a novel prognostic biomarker for GC,
either alone or in combination with cyclin D1.
Methods
Patients and specimens
Fresh primary cancer and paired adjacent normal tissue
specimens were collected from 48 GC patients (33 males
and 15 females) in the Department of General Surgery
of Shanghai General Hospital. The tissues were collected
after surgical resection, frozen immediately in liquid
nitrogen, and stored at −80 °C until RNA and protein
extraction. A total of 264 preserved human GC tissue
specimens (from 157 males and 107 females) from
Shanghai General Hospital were paraffin embedded for
TMA construction. Disease-free survival (DFS) and
overall survival (OS) were defined as the interval from
surgery to clinically or radiologically proven recurrence/
metastasis and death, respectively. Tumor staging was
based on pathological outcomes according to the guide-
lines of the International Union against Cancer (UICC)
[28], and the diagnoses were confirmed by two patholo-
gists. Patients who had never received chemotherapy or
radiotherapy were enrolled in this study. All of the
patients provided written informed consent. The study
was approved by the Ethics Committee of Shanghai
General Hospital.
Cell lines and the establishment of HOXA1 knockdown
cell lines
The human gastric cancer cell lines HGC-27, SGC-7901,
MGC-803, BGC-823, and AGS were purchased from the
Type Culture Collection of the Chinese Academy of
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Science (Shanghai, China). Cells were cultured in 1640/
F12k medium supplemented with 10 % fetal bovine serum
(FBS; Gibco, Australia) and 1 % penicillin–streptomycin at
37 °C in a humidified atmosphere containing 5 % CO2.
The HOXA1 RNAi lentiviral expression plasmid was
purchased from Scigebio Biotechnology Co., Ltd. (Shanghai,
China). The oligonucleotides used to generate the shRNA
targeting HOXA1 (shHOXA1) were forward: AGTTATCT
TAGCTGGATATAA and reverse: TTATATCCAGCTAA
GATAACT. SGC-7901 and BGC-823 cells were transfected
with 1 × 108 transducing units/mL of lentivirus parti-
cles. The cells were subjected to antibiotic selection
(with 1.2 μg/mL puromycin) after transfection. As a
result, two stable cell lines (SGC-7901-shHOXA1 and
BGC-823-shHOXA1) were established. Cells trans-
fected with a control shRNA sequence were used as
controls (SGC-7901-Control and BGC-823-Control).
RNA extraction and quantitative real-time PCR (qRT-PCR)
Total RNA from GC cells and tissue specimens was
extracted with TRIzol reagent (Invitrogen, NY, USA)
according to the manufacturer’s instructions, and 2 μg of
total RNA from each sample were reverse transcribed
into cDNA using PrimeScript™ RT Master Mix (Perfect
Real Time; Takara, Shiga, Japan) according to the manu-
facturer’s instructions. qRT-PCR was performed using
SYBR® Premix Ex Taq™ (Tli RNaseH Plus; Takara) in a
ViiA™ 7 Real-time PCR System (Applied Biosystems, NY,
USA) according to the manufacturer’s protocol. The ampli-
fication was performed as follows: an initial denaturation
step for 2 min at 95 °C followed by 40 cycles of denatur-
ation for 10 s at 95 °C, annealing for 30 s at 59 °C, and
elongation for 30 s at 72 °C, and a final extension step at
72 °C for 30 s. The specific primers used were as follows:
HOXA1 sense, 5'-CGGCTTCCTGTGCTAAGTCT-3' and
antisense, 5'-TTCATTGTGCCATCCATCAC-3'; cyclin D1
sense, 5'-GTGTATCGAGAGGCCAAAGG-3' and anti-
sense, 5'-GCAACCAGAAATGCACAGAC-3'; and β-actin
sense, 5'-CATGTACGTTGCTATCCAGGC-3' and anti-
sense, 5'-CTCCTTAATGTCACGCACGAT-3'. β-Actin was
used as an internal control, and the relative quantities
(Δ cycle threshold [Ct] values) of each transcript were
normalized to β-actin. Each reaction was repeated in
triplicate. The fold changes (2−ΔΔCt) in HOXA1 and
cyclin D1 mRNA expression were calculated using the
following formulae: HOXA1ΔCt = (Avg. HOXA1_Ct -
Avg. β-actin_Ct), HOXA1ΔΔCt = (HOXA1ΔCt_tumor -
HOXA1ΔCt_non-tumor); cyclin D1ΔCt = (Avg. cyclin
D1_Ct - Avg. β-actin_Ct), cyclin D1ΔΔCt = (cyclin
D1ΔCt_tumor - cyclin D1ΔCt_non-tumor).
Protein extraction and western blotting
Total protein was isolated from GC cells and tissue speci-
mens using RIPA Lysis Buffer (Beyotime Biotechnology,
Jiangsu, China). Protein concentration was measured
using the BCA protein assay kit (Beyotime Biotechnology).
Samples containing 40 μg of protein were separated by
10 % sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE), and the separated proteins were
then transferred onto PVDF membranes. The membranes
were blocked in 5 % fat-free milk solution containing
0.1 % Tween-20 for 1 h at room temperature. Membranes
were then incubated with an anti-HOXA1 antibody
(1:1,000; Abcam, Cambridge, UK), an anti-cyclin D1 anti-
body (1:100; Abcam), and an anti-α/β-tubulin antibody
(1:1,000; Cell Signaling Technology, MA, USA) at 4 °C
overnight. Next, the membranes were incubated with a
secondary antibody (1:10,000; Jackson ImmunoReasearch
Inc., PA, USA) conjugated to horseradish peroxidase for
1 h at room temperature. After washing with TBST buffer,
the bands were visualized with Immobilon™ Western
Chemiluminescent HRP Substrate (Millipore, MA, USA)
according to the manufacturer’s instructions.
Cell counting Kit-8 (CCK-8) assay
To observe the effect of HOXA1 knockdown on cell pro-
liferation in vitro, the CCK-8 assay (Dojindo, Kumamoto,
Japan) was employed to generate cell growth curves.
Briefly, cells were plated in triplicate in 96-well cell culture
plates at a density of 2,000 cells/well. At various time
points (24, 48, 72, 96, and 120 h), the cells were incubated
with 10 μL of CCK-8 solution for 2 h at 37 °C, and then
the absorbance at 450 nm was measured on a Gen5
microplate reader (BioTek, VT, USA). The experiment
was performed independently in triplicate.
Plate colony formation assay
To evaluate colony formation, 800 log-phase cells were
seeded in 6-well plates. After a 14-day incubation, the
cells were fixed in methyl alcohol for 15 min and dyed
with crystal violet for 15 min. Colonies were then
counted, and the plates were photographed. The experi-
ment was performed independently in triplicate.
Migration and invasion assays
For these assays, 1 × 105 cells in serum-free medium
were seeded in the upper compartment of a transwell
chamber (Millipore). The transwell membrane was
either coated with Matrigel (for invasion; BD, CA, USA)
or without (for migration). Then, the lower chamber was
filled with 600 μL of basal medium containing 10 % FBS.
After incubation at 37 °C in a humidified incubator
containing 5 % CO2 for 24 h, the migrated or invaded
cells on the lower membrane were fixed with methanol,
stained with crystal violet, and then counted. The experi-
ment was performed independently in triplicate.
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Nude mice xenograft models
Four-week-old male BALB/C nude mice were used to
establish GC xenografts. The mice were then randomly
divided into 2 groups (n = 5), and 5 × 106 BGC-823-
shHOXA1 or BGC-823-Control cells suspended in
100 μL of PBS were subcutaneously injected into their
flanks. All mice were sacrificed 21 days after injection.
Then, tumor mass and size were measured. Tumor
volume was calculated using the following formula:
volume = width2 × length × 0.5 [29]. Paraffin sections of
the xenograft tissues were prepared for hematoxylin and
eosin (H&E) staining and IHC with an anti-Ki67 anti-
body (1:500; Abcam). All animal studies were performed
in accordance with the Shanghai General Hospital
Animal Care guidelines. All efforts were made to
minimize animal suffering.
Flow cytometry analysis of the cell cycle
The Cell Cycle Kit (BD) was utilized to analyze the cell
cycle. Cells were harvested, washed in phosphate buff-
ered saline (PBS) for 5 min, and collected by centrifuga-
tion at 1,000 rpm for 10 min. Then, 5 mL of prechilled
70 % ethanol was used to fix the cells overnight at 4 °C.
The cells were then washed, centrifuged, and resus-
pended in 0.5 mL of PI/RNase Staining Buffer. After
incubation for 15 min, the cells were analyzed by flow
cytometry (BD Accuri). The experiment was performed
independently in triplicate.
5-Ethynyl-2′- deoxyuridine (EdU) incorporation assay
The EdU incorporation assay was performed using
the Cell-Light™ EdU Apollo® 643 In Vitro Imaging Kit
(RiboBio, Guangzhou, China) according to the manu-
facturer’s instructions. Cells were seeded on confocal
dishes; when they reached about 50 % confluency,
EdU labeling medium was added, and the cells were
incubated for about 2 h. The cells were then fixed with
4 % formaldehyde for 30 min and treated with 0.5 %
Triton X-100 for 30 min at room temperature. After
washing three times with PBS, the cells were dyed with
Apollo for 30 min. Then, Hoechst 33342 (5 μg/mL) was
used to dye the DNA in the cells, and the cells were visu-
alized with a confocal microscope. The experiment was
performed independently in triplicate.
Tissue microarray (TMA) construction and
immunohistochemistry (IHC)
The method used to construct the TMA was previously
reported [15]. After dewaxing and rehydration, the
paraffin-embedded sections were drowned in boiled
citrate buffer (0.01 M, pH 6.0) for antigen retrieval.
Next, an anti-HOXA1 antibody (1:100; Abcam) and
anti-cyclin D1 antibody (1:50; Abcam) were incubated
with the slides at 4 °C overnight. Then, the anti-mouse
or anti-rabbit EnVision™ two-step Visualization System
(Gene Tech, Shanghai, China) was used to detect the
primary antibody for 30 min at room temperature.
Finally, the slides were counterstained with Mayer’s
hematoxylin and covered with coverslips.
Evaluation of immunostaining
We semi-quantitatively scored the expression levels of
HOXA1 and cyclin D1 by calculating the staining inten-
sity and area, according to the method of Han et al. [15],
with slight modifications. The staining intensity was scored
as 0 (negative), 1 (weak), 2 (moderate), or 3 (strong). The
staining area was scored as 0 (0 %), 1 (1–25 %), 2
(26–50 %), or 3 (51–100 %) based on the percentage
of positively stained cells. The final immunostaining
score (IS) for each case was calculated by adding the
staining intensity score to the staining area score. Accord-
ing to the IS, our specimens were divided into 2 groups as
follows: positive HOXA1 and cyclin D1 expression was
defined as an IS ≥3 (3, 4, 5, and 6), and negative expres-
sion was defined as an IS <3 (0 and 2).
Statistical analysis
All statistical analyses were carried out using SPSS
version 19.0 (SPSS, Inc., Chicago, IL, USA). The 2-tailed
Student’s t-test was used to calculate the difference in
the mRNA expression of HOXA1 and cyclin D1 between
cancer tissues and paired normal mucosae. The correl-
ation between HOXA1 and cyclin D1 mRNA and protein
expression was calculated using Spearman’s correlation
coefficient test. The significance of the differences among
covariates was determined using two-tailed χ2 or Fisher’s
exact tests where appropriate. The Kaplan-Meier method
was used to calculate the survival rates, and the log-rank
test was used to compare survival curves. Cox propor-
tional hazards models were utilized to investigate the
independent risk factors for death, and significant factors
were selected for the final multivariate regression model.
The in vitro and in vivo data were expressed as mean ±
SD and were compared using the 2-tailed Student’s t-test.
Differences with P values less than 0.05 were considered
statistically significant.
Results
HOXA1 is upregulated in GC tissues compared to the
levels in corresponding adjacent normal mucosae
The mRNA expression of HOXA1 was examined in 48
GC tissue and paired mucosa samples by qRT-PCR. A
majority of the GC samples (32, 66.7 %) showed a ≥2-
fold increase in HOXA1 mRNA levels compared with
the levels in adjacent normal mucosae (Fig. 1a). The
relative expression (ΔCt) of HOXA1 mRNA in cancerous
tissue was significantly lower than that in normal mu-
cosa (9.57 ± 1.84 vs. 11.23 ± 1.66, respectively; P < 0.001).
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Similarly, western blotting revealed a significant eleva-
tion of HOXA1 protein expression in GC tissues
compared with the expression in adjacent normal mu-
cosae (Fig. 1b), suggesting that HOXA1 expression
was elevated at both the transcriptional and transla-
tional levels.
Knockdown of HOXA1 expression inhibits GC cell
proliferation
To explore the function of HOXA1 in GC, we sup-
pressed the expression of HOXA1. Western blotting
demonstrated that HOXA1 expression was higher in
SGC-7901 and BGC-823 cells than in the other tested
cell lines (Fig. 2a, b). The efficiency of shRNA-
mediated knockdown in SGC-7901 and BGC-823 cells
was confirmed by western blotting and qRT-PCR (Fig. 2c,
d). Next, we performed CCK-8 and plate colony formation
assays to assess the role of HOXA1 in GC cell growth. As
shown in Fig. 2e, significant inhibition of cell growth was
observed in the sh-HOXA1 group compared with the
growth in the control groups. In addition, the colony
formation assay showed that HOXA1 knockdown re-
duced colony formation compared with that in the con-
trol group (P < 0.001; Fig. 2f, g). These results indicated
that knockdown of HOXA1 expression inhibited GC
cell proliferation.
Knockdown of HOXA1 expression inhibits GC cell
migration and invasion
Cell migration and invasion are necessary for tumor de-
velopment and metastasis. We used transwell chambers
either uncoated or precoated with Matrigel to assess the
effects of HOXA1 expression on cell migration and inva-
sion, respectively. Knockdown of HOXA1 inhibited the
migration and invasion of GC cells compared with that
of the control cells (P < 0.001; Fig. 3), indicating that
HOXA1 increases the migrant and invasive behavior of
these cells. These findings indicated that upregulation of
HOXA1 may contribute to GC progression by promoting
cell migration and invasion.
Knockdown of HOXA1 expression inhibits xenograft
tumor growth
To determine the role of HOXA1 in tumorigenesis,
BGC-823-shHOXA1 cells and BGC-823-Control cells
were subcutaneously injected into nude mice, and the
resulting tumors were isolated 3 weeks later. As shown
in Fig. 4, the growth index of the tumors in the BGC-
823-shHOXA1 group was significantly lower than that
of tumors in the BGC-823-Control group. Moreover,
HOXA1 knockdown significantly inhibited overall tumor
growth as assessed by the measurements of tumor
volume and mass (P < 0.05 and P < 0.01, respectively;
Fig. 4b, c). Particularly, the average tumor volume and
Fig. 1 Expression of HOXA1 and cyclin D1 in human gastric cancer (GC) tissues. a Relative HOXA1 and cyclin D1 mRNA expression in 48 tumor
tissues and paired adjacent normal mucosae as determined by qRT-PCR. An increase (at least 2-fold) in HOXA1 and cyclin D1 mRNA levels compared
to noncancerous tissue was observed in 32 (66.7 %) and 29 (60.4 %) of the GC tissue samples. The 2-ΔΔCt method was used to calculate the fold
change. b Western blotting showed higher HOXA1 protein expression in GC tissues than in the matched adjacent normal mucosae. c Western blotting
showed that cyclin D1 protein expression was upregulated in GC tissues compared to the levels in the matched adjacent normal mucosae
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weight of the BGC-823-shHOXA1 group were dramatic-
ally lower than those of the BGC-823-Control group;
tumor volume at 3 weeks was 34.29 ± 21.80 mm3 vs.
288.70 ± 183.82 mm3, respectively, and tumor weight
was 23.80 ± 15.66 mg vs. 176.40 ± 88.25 mg, respectively.
In addition, IHC was utilized to detect Ki67, a cellular
proliferation marker, in the xenografts. The expression
of Ki67 was significantly weaker in the xenografts
Fig. 2 HOXA1 expression in cell lines and the effects of HOXA1 knockdown in GC cell lines. a HOXA1 protein levels in five GC cell lines and
b grayscale values were evaluated. SGC-7901 and BGC-823 showed higher HOXA1 expression than the other tested cell lines. c Western blotting
analysis of HOXA1 expression in stable HOXA1 knockdown SGC-7901 and BGC-823 cell lines. d Real-time PCR analysis of HOXA1 expression in
stable HOXA1 knockdown SGC-7901 and BGC-823 cell lines. e Effect of HOXA1 knockdown on cell growth was evaluated by the Cell Counting
Kit-8 assay. Cell growth was inhibited by HOXA1 knockdown. f A plate colony formation assay was performed to assess the impact of HOXA1
knockdown on cell growth. HOXA1 knocked down GC cells showed a weaker clone formation. g The number of GC cell clones was quantified.
(**P < 0.01, ***P < 0.001)
Yuan et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:15 Page 6 of 16
containing BGC-823-shHOXA1 cells than in xenografts
containing BGC-823-Control cells (Fig. 4d). These find-
ings showed that downregulation of HOXA1 expression
suppressed GC tumor growth in vivo.
Knockdown of HOXA1 expression induces changes in the
cell cycle of GC cells and decreases cyclin D1 expression
Next, we utilized flow cytometry analysis to determine
the role of HOXA1 in the cell cycle and found that
HOXA1 knockdown cells were arrested in the G1
phase and the number of S phase cells was reduced
(Fig. 5a, b). Then, we used an EdU incorporation
assay to determine how HOXA1 knockdown affects
the number of proliferating cells. The results showed
that the number of EdU-positive cells in the sh-
HOXA1 group was lower than that in the control
group (Fig. 5c, d). As EdU is incorporated into DNA
during synthesis in S phase, fewer EdU-positive cells
means a reduction of the number of cells in S phase,
which is in accord with the cell cycle analysis results.
Cyclin D1 has been reported to play an important
role in cell cycle progression, mainly via regulation of
the G1-S-phase transition [30]. Then, we assessed
cyclin D1 expression in our established stable GC
cells and found that expression was markedly lower
in SGC-7901-shHOXA1 and BGC-823-shHOXA1 cells
than in the control cells (Fig. 5e). These results indi-
cated that HOXA1 knockdown induced an accumula-
tion of SGC-7901 and BGC-823 cells in the G1 phase
and a reduction in the number of cells in S phase
and the expression of cyclin D1.
Cyclin D1 is upregulated in GC tissues compared with the
levels in the corresponding adjacent normal mucosae
We then determined the mRNA expression of cyclin
D1 in GC tissues and paired mucosae. Twenty-nine
(60.4 %) of the GC samples showed a ≥2-fold increase
in cyclin D1 mRNA levels compared with the levels
Fig. 3 Knockdown of HOXA1 expression inhibits GC cell migration and invasion. a The effect of HOXA1 knockdown on the migration of GC cells
using transwell chambers without Matrigel. b The number of migrated cells was significantly lower in the sh-HOXA1 group than in the control groups
(Control and Mock). c The effect of HOXA1 knockdown on GC cell invasion using transwell chambers coated with Matrigel. d The number of invaded
cells was significantly lower in the sh-HOXA1 group than in the control groups (Control and Mock). Original magnification, 200×. (***P < 0.001)
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in the adjacent normal mucosae (Fig. 1a). The relative
expression (ΔCt) of cyclin D1 mRNA in GC was signifi-
cantly lower than that in normal mucosae (4.74 ± 1.34 vs.
5.77 ± 1.35, respectively; P < 0.001). Interestingly, increased
HOXA1 and cyclin D1 mRNA levels were detected in 27
(56.3 %) GC tissues, and a statistically significant
correlation was found (r = 0.651, P < 0.001). Similarly,
western blotting revealed a significant elevation of cyclin
D1 protein expression in GC tissues compared with the
levels in the adjacent normal mucosae (Fig. 1c), suggest-
ing that cyclin D1 expression is elevated at both the
transcriptional and translational levels.
Fig. 4 Knockdown of HOXA1 expression suppresses tumorigenicity in vivo. a BGC-823-shHOXA1 and BGC-823-Control cells were injected subcutaneously
into nude mice. After 3 weeks, the tumors were dissected. The tumors of mice in the BGC-823-shHOXA1 group were smaller than the tumors of BGC-
823-Control group. b Tumor volume of the BGC-823-Control and BGC-823-shHOXA1 groups 3 weeks after cell injection (*P< 0.05). c Tumor weight of
the BGC-823-Control and BGC-823-shHOXA1 groups 3 weeks after cell injection (**P< 0.01). d H&E- and IHC-stained paraffin-embedded sections obtained
from the xenografts. IHC staining showed that the expression of Ki67 was weaker in the BGC-823-shHOXA1 group than in the BGC-823-Control group.
Original magnification, 200×
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Correlation of HOXA1 and cyclin D1 expression with
clinicopathological parameters
The expression of HOXA1 and cyclin D1 was assessed by
IHC analysis using a TMA of 264 primary GC cases paired
with normal mucosae and 104 metastatic lymph nodes.
We detected significant differences in HOXA1 expres-
sion among normal mucosae, GC tissues, and LNM
(Table 1, P < 0.001). HOXA1 staining was mainly ob-
served in the nuclei of GC cells, and was detected in the
cytoplasm (Fig. 6). As shown in Table 1, HOXA1 was
obviously upregulated in 54.5 % (144/264) of the primary
cancer specimens, whereas HOXA1 was upregulated in
only 23.1 % (61/264) of adjacent normal mucosae.
HOXA1 expression in LNM (71.2 %) was much higher
than that in GC tissues (54.5 %), and this difference was
significant (P = 0.004). The associations between HOXA1
expression and various clinicopathological parameters
are shown in Table 2. Elevated HOXA1 expression was
significantly associated with the International Union
against Cancer (UICC) stage (P < 0.001), invasion depth
(P = 0.040), nodal involvement (P = 0.004), and differenti-
ation (P < 0.001; Table 2).
Fig. 5 HOXA1 knockdown induces marked cell cycle arrest. a Flow cytometry results showing the cell phase distribution of GC cells. HOXA1 knockdown
cells (the sh-HOXA1 group) show G1 phase arrest and a reduced number of cells in S phase compared to cells in the control groups. b The percentages
of cells in each phase were quantified (cell phase distribution). c Proliferating SGC-7901 and BGC-823 cells were labeled with EdU and Hoechst33342.
EdU staining is shown in red, and Hoechst33342 staining is shown in blue, an overlay of the EdU and Hoechst 33342 stained images are shown. Fewer
EdU-positive cells were detected in the sh-HOXA1 group than the control groups, which is indicative of a reduction of the number of cells in S phase in
the sh-HOXA1 group compared to that in the control. d The percentage of EdU-positive cells was quantified. e Western blot analysis of
cyclin D1 expression in stable HOXA1 knockdown SGC-7901 and BGC-823 cell lines. (*P < 0.05, **P < 0.01, ***P < 0.001)
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In addition, significant differences were detected for the
cyclin D1 expression in normal mucosae, GC tissues, and
LNM (Table 1, P < 0.001). Of the 264 primary cancer spec-
imens, 51.9 % (137/264) showed positive cyclin D1 expres-
sion, whereas only 12.5 % (33/264) of the adjacent normal
mucosae were positive (Table 1). However, no significant
difference in cyclin D1 expression was found between GC
tissues and LNM (Table 1, P = 0.132). Overexpression of
cyclin D1 was significantly associated with differentiation
(Table 2, P = 0.044).
In addition, of the 144 specimens with positive
HOXA1 expression, 73.6 % (106/144) showed positive
Table 1 Expression of HOXA1 and cyclin D1 in normal mucosae, GC tissues, and lymph node metastases
Expression of HOXA1
or cyclin D1
Tissue samples P value
Normal mucosae
(n = 264) (%)
GC tissues
(n = 264) (%)
LNM
(n = 104) (%)
HOXA1
Negative 203 (76.9) 120 (45.5) 30 (28.8) <0.001*,**
Positive 61 (23.1) 144 (54.5) 74 (71.2) 0.004*,***
cyclin D1
Negative 231 (87.5) 127 (48.1) 41 (39.4) <0.001*,****
Positive 33 (12.5) 137 (51.9) 63 (60.6) 0.132
HOXA1/cyclin D1
Both negative 170 (64.4) 89 (33.7) 24 (23.1) <0.001*,*****
One positive 94 (35.6) 69 (26.1) 23 (22.1) 0.033*,******
Both positive 0 (0.00) 106 (40.2) 57 (54.8)
GC gastric cancer
LNM lymph node metastases
P value calculated using chi-square test or Fisher's exact test
*Significant difference
Significant difference in the expression of HOXA1**, cyclin D1****, or HOXA1/cyclin D1***** among normal mucosae, GC tissues, and LNM
Significant difference in the expression of HOXA1*** and HOXA1/cyclin D1****** between GC tissues and LNM
Fig. 6 Immunohistochemical staining of HOXA1 expression in normal and gastric cancer tissues. HOXA1 staining was observed mainly in the
nuclei of GC cells and in the cytoplasm. HOXA1 expression was much higher in the GC tissues than in the adjacent normal mucosae. Normal
gastric tissue showing negative HOXA1 expression (a); Positive HOXA1 staining in moderately differentiated GC tissue (b), signet ring cell carcinoma
(c) and metastatic lymph nodes (d). Original magnification, 200× (400× for inset images)
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cyclin D1 expression. We found a statistically significant
correlation between HOXA1 and cyclin D1 expression
(r = 0.476, P < 0.001, Table 3), and HOXA1 and cyclin
D1 expression were detected in the same location of one
tumor specimen (Fig. 7). These results demonstrated
that there was a correlation between HOXA1 and cyclin
D1 in GC.
Survival analysis and prognostic significance of HOXA1
and/or cyclin D1 expression
To assess the possible association between the expression
of HOXA1 and/or cyclin D1 in GC tumors and patient
survival, Kaplan-Meier curves and the log-rank test were
used to determine DFS and OS in 264 patients who
underwent radical gastrectomy (Fig. 8). Patients with
HOXA1-positive tumors had a poorer DFS (P < 0.001)
and OS (P < 0.001) than patients with HOXA1-negative
tumors (Fig. 8a). Cyclin D1 was also significantly associ-
ated with DFS (P < 0.001) and OS (P < 0.001; Fig. 8b). To
assess concomitant HOXA1 and cyclin D1 protein expres-
sion, we divided the specimens into three groups: group 1,
tumors exhibiting no HOXA1 or cyclin D1 expression
(HOXA1-/cyclin D1-, 89 specimens); group 2, tumors
with abnormal expression of one protein (HOXA1-/cyclin
Table 2 Relationship between clinicopathologic parameters and HOXA1 or cyclin D1 protein expression in gastric cancer (n = 264)
Characteristics Total HOXA1 expression P value Cyclin D1 expression P value
Negative (120) Positive (144) Negative (127) Positive (137)
Age(years) 0.457 0.845
<65 121 58 63 59 62
≥65 143 62 81 68 75
Gender 0.095 0.712
Male 157 78 79 77 80
Female 107 42 65 50 57
T stage 0.040* 0.816
T1 76 44 32 38 38
T2 42 20 22 22 20
T3 118 47 71 53 65
T4 28 9 19 14 14
N stage 0.004* 0.179
N0 116 67 49 56 60
N1 91 35 56 48 43
N2 40 13 27 19 21
N3 17 5 12 4 13
M stage 0.355 0.751
M0 254 117 137 123 131
M1 10 3 7 4 6
UICC stage <0.001* 0.400
I 95 54 41 49 46
II 48 28 20 24 24
III 89 28 61 43 46
IV 32 10 22 11 21
Differentiation <0.001* 0.044*
High 47 33 14 30 17
Moderate 42 20 22 21 21
Low 175 67 108 76 99
*Significant association among variables (P < 0.05)
Table 3 Association between HOXA1 and cyclin D1 expression
in gastric cancer tissues
Sample Cyclin D1 expression r P value
Negative Positive
HOXA1 negative 89 31 0.476 <0.001
HOXA1 positive 38 106
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D1+ or HOXA1+/cyclin D1-, 69 specimens); and group 3,
tumors with abnormal expression of both proteins
(HOXA1+/cyclin D1+, 106 specimens). Group 1 showed
better DFS and OS than group 2, and group 3 showed the
worst DFS and OS (P < 0.001; Fig. 8c).
In univariate analysis, patients with HOXA1-positive or
cyclin D1-positive tumors had a markedly lower OS and
DFS than patients with HOXA1-negative or cyclin D1-
negative tumors (HOXA1, OS, HR 4.601 [95 % CI
2.504–8.454], P < 0.001, DFS, HR 4.438 [95 % CI
2.418–8.145], P < 0.001; cyclin D1, OS, HR 5.893
[95 % CI 3.159–10.990], P < 0.001, DFS, HR 5.673
[95 % CI 3.044–10.572], P < 0.001) (Table 4). Further-
more, lower OS and DFS were also observed in patients
with both HOXA1-positive and cyclin D1-positive tumors
(OS, HR 9.064 [95 % CI 4.278–19.203], P < 0.001; DFS,
HR 8.495 [95 % CI 4.021–17.948], P < 0.001; Table 4). The
multivariate analysis demonstrated that the expression of
both HOXA1 and cyclin D1 was an independent
prognostic factor for OS (HR 9.905 [95 % CI 4.453–
22.031]; P < 0.001) and DFS (HR 8.636 95 % CI
[3.916–19.047]; P < 0.001), but not the expression of
HOXA1 or cyclin D1 alone (Table 4).
Discussion
It is well known that tumor cells and embryonic stem cells
share some common pathways related to self-renewal and
proliferation and that stem cell genes can play direct roles
in tumor progression and/or act as valuable markers of
tumorigenesis [31, 32]. HOX genes are typical examples of
the close relationship between embryogenesis and tumori-
genesis [33]. In general, HOX genes are master regulators
of embryonic development and stem cell differentiation;
however, their misexpression can lead to changes in
Fig. 7 Expression of HOXA1 and cyclin D1 in normal, tumor, and metastatic lymph node tissues. HOXA1 and cyclin D1 expression were detected
in the same location in one tumor specimen. Negative HOXA1 and cyclin D1 staining in normal gastric tissue (a-b). Positive HOXA1 and cyclin D1
staining in GC tissue (c-d), and metastatic lymph nodes (e-f). Original magnification, 200×
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cancer-associated properties, such as proliferation, migra-
tion, invasion, and survival [34, 35]. HOXA1, a HOX gene,
is a pivotal transcriptional regulator of early embryonic
development that plays a critical role in the development
of the brainstem, inner ear, and heart in humans and mice
[36, 37]. Overexpression of HOXA1 is associated with a
variety of human tumors, including breast, lung, skin,
liver, and prostate [18, 19, 21, 38–40]. However, the num-
ber of studies on HOXA1 expression during GC tumori-
genesis and progression are very limited.
In the present study, we showed for the first time that
both HOXA1 mRNA and protein expression were up-
regulated in primary GC tissues compared with the
levels in adjacent normal mucosae. To further elucidate
the role of HOXA1 in tumor progression, an shRNA-
based strategy was used to stably knockdown HOXA1
expression in SGC-7901 and BGC-823 cells, which typ-
ically express high levels of HOXA1 protein. Then, we
determined, for the first time, that HOXA1 knockdown
inhibited GC cell proliferation using CCK-8 and colony
formation assays. Moreover, knockdown of HOXA1 ex-
pression also led to a significant reduction in xenograft
tumor formation. Recently, Wardwell-Ozgo et al. [18]
showed that HOXA1 has a potent effect on cell invasion
in melanoma. Meanwhile, Wang et al. [40] reported that
HOXA1 knockdown inhibits the growth, invasion, and
migration of prostate cancer cells. Coincidentally, our
study revealed that HOXA1 knockdown in GC cells sup-
pressed migration and invasion, which indicates the po-
tential involvement of HOXA1 in tumor metastasis.
These in vitro and in vivo data suggest that HOXA1
functions in GC cell proliferation, migration, invasion,
and tumorigenesis.
Our study showed that knockdown of HOXA1 expres-
sion had a marked effect on GC cell proliferation. As the
cell cycle is closely related to cell proliferation, we ana-
lyzed the effect of HOXA1 knockdown on the cell cycle
and found that these cells were arrested in the G1 phase
and the number of S phase cells was reduced. Then, we
performed an EdU incorporation assay to determine the
Fig. 8 Kaplan-Meier analysis of disease-free survival (DFS) and overall survival (OS) in 264 GC patients. a DFS and OS of patients according to HOXA1
expression levels determined by immunohistochemical staining. The survival rate of patients with HOXA1-positive tumors was significantly lower than
that of patients with HOXA1-negative tumors (P < 0.001). b DFS and OS were significantly worse in patients with cyclin D1-positive tumors than in
patients with cyclin D1-negative tumors (P < 0.001). c DFS and OS were significantly lower in patients with HOXA1- and cyclin D1-positive tumors than
in patients with HOXA1- and cyclin D1-negative tumors (P < 0.001)
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role of HOXA1 in GC progression. The results of the EdU
incorporation assay showed that HOXA1 knockdown sup-
pressed GC cell proliferation. More importantly, as EdU is
incorporated into DNA during synthesis, the decreased
number of EdU-incorporated SGC-7901-shHOXA1 and
BGC-823-shHOXA1 cells suggested that the cell cycle
Table 4 Univariate and multivariate analysis for overall survival (OS) and disease-free survival (DFS)
OS DFS
Univariate Multivariate Univariate Multivariate
Variable HR (95 % CI) P value HR (95 % CI) P value HR (95 % CI) P value HR (95 % CI) P value
HOXA1/cyclin D1
Both negative 1 1 1 1
One positive 1.623(0.643-4.099) 0.305 1.800(0.702-4.615) 0.221 1.577(0.625-3.983) 0.335 1.674(0.652-4.297) 0.284
Both positive 9.064(4.278-19.203) <0.001* 9.905(4.453-22.031) <0.001* 8.495(4.021-17.948) <0.001* 8.636(3.916-19.047) <0.001*
HOXA1
Negative 1 1
Positive 4.601(2.504-8.454) <0.001* 4.438(2.418-8.145) <0.001*
Cyclin D1
Negative 1 1
Positive 5.893(3.159-10.990) <0.001* 5.673(3.044-10.572) <0.001*
Age(years)
<65 1 1 1
≥65 1.880(1.103-3.202) 0.020* 1.862(1.093-3.172) 0.022* 1.738(1.011-2.987) 0.046*
Gender
Male 1
Female 1.002(0.603-1.666) 0.992 1.006(0.605-1.671) 0.982
T stage
T1 1 1
T2 2.787(0.786-9.885) 0.113 2.871(0.809-10.183) 0.103
T3 7.596(2.709-21.302) <0.001* 7.543(2.690-21.150) <0.001*
T4 12.061(3.928-37.036) <0.001* 12.200(3.973-37.465) <0.001*
N stage
N0 1 1
N1 4.023(1.799-8.999) 0.001* 4.048(1.810-9.054) 0.001*
N2 9.647(4.238-21.959) <0.001* 9.489(4.170-21.592) <0.001*
N3 16.913(6.668-42.899) <0.001* 18.152(7.149-46.088) <0.001*
M stage
M0 1 1
M1 3.082(1.232-7.709) 0.016* 3.405(1.361-8.518) 0.009*
UICC stage
I 1 1 1 1
II 6.795(1.869-24.701) 0.004* 8.168(2.241-29.773) 0.001* 6.867(1.889-24.962) 0.003* 7.172(1.961-26.222) 0.003*
III 13.458(4.100-44.180) <0.001* 14.327(4.325-47.457) <0.001* 13.355(4.069-43.834) <0.001* 12.571(3.791-41.678) <0.001*
IV 32.066(9.433-109.001) <0.001* 30.392(8.750-105.567) <0.001* 34.583(10.172-117.570) <0.001* 33.649(9.676-117.020) <0.001*
Differentiation
High 1 1
Moderate 5.441(1.155-25.634) 0.032* 5.499(1.167-25.909) 0.031*
Low 8.506(2.070-34.961) 0.003* 8.581(2.088-35.268) 0.003*
HR hazard ratio; CI confidence interval
*P < 0.05 indicates that the 95 % CI of the HR did not include 1
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was arrested in the G1 phase, which was validated in our
previous cell cycle analysis showing that the number of S
phase cells was reduced.
As our data show, downregulation of HOXA1 expres-
sion suppressed GC cell proliferation mainly by inhibit-
ing the cell cycle. Recently, HOXA1 was reported to
stimulate the transcription of cyclin D1, which increases
cell proliferation and survival [21]. Another important
experiment indicated that upregulation of HOXA1 acti-
vated the transcription of cyclin D1 and promoted the
G1-S transition in cancer cells [41]. Cyclin D1 plays an
important role in cell cycle progression, mainly by affect-
ing regulation of the G1-S-phase transition [30]. Several
studies have identified cyclin D1 as involved early in the
development of GC [23, 42, 43]. Then, we assessed the
expression of cyclin D1 by western blotting in our estab-
lished stable GC cells. We found that cyclin D1 expres-
sion was dramatically decreased in SGC-7901-shHOXA1
and BGC-823-shHOXA1 cells compared to the levels in
the corresponding control cells, which indicates that
HOXA1 influences tumor cell proliferation by regulating
cyclin D1.
Next, we analyzed the relationship between HOXA1
and cyclin D1 on a histological level. We detected the
mRNA and protein expression of cyclin D1 and found
that both were higher in primary GC tissues than in nor-
mal mucosae. Interestingly, increased HOXA1 and cyc-
lin D1 mRNA levels were detected in 27 (56.3 %) GC
tissue samples, and a statistically significant correlation
was detected between them (r = 0.651, P < 0.001). Then,
to evaluate the relationship between HOXA1 expression
and clinicopathological parameters, we used IHC on a
GC TMA with an expanded number of tissue samples
and found that HOXA1 expression was significantly
associated with UICC stage, invasion depth, nodal in-
volvement, and differentiation. Furthermore, cyclin D1
was more frequently detected in areas of positive
HOXA1 staining in GC tissues, and a significant correl-
ation was found between HOXA1 and cyclin D1 expres-
sion (r = 0.476, P < 0.001). Thus, the intimate relationship
between HOXA1 and cyclin D1 was confirmed at the
histological level.
Recent research indicated that HOXA1 expression is
markedly correlated with the overall survival of patients
with hepatocellular carcinoma [39]. However, the prog-
nostic value of HOXA1 in GC has not been evaluated.
According to the work by Wardwell-Ozgo et al., patients
with a higher HOXA1 signature had a shorter time to
distant metastasis events [18], suggesting the prognostic
implications of HOXA1. And our results also showed
that HOXA1 could serve as a prognostic marker for GC
with a HR of 4.60 for OS and 4.44 for DFS. Intriguingly,
survival analysis indicated that HOXA1-and cyclin D1-
positive cases had shorter survival time than HOXA1-or
cyclin D1-negative cases. What’s more, univariate ana-
lysis demonstrated that HOXA1-and cyclin D1-positive
patients exhibited a much higher HR for OS (9.06 vs
1.62) and DFS (8.50 vs 1.58) than HOXA1-or cyclin D1-
positive patients, indicating that the combination of
HOXA1 and cyclin D1 may better prognosticate clinical
outcome for GC. Finally, multivariate Cox model ana-
lysis confirmed that HOXA1 combined with cyclin D1
was an independent prognostic factor for DFS and OS in
GC. Thus, these results suggested that HOXA1, either
alone or in combination with cyclin D1, could be a novel
prognostic biomarker for GC patients.
Conclusion
Our research results showed that HOXA1 plays an
important role in GC clinical prognosis. First, our data
indicated that HOXA1 and cyclin D1 mRNA and
protein expression were higher in GC tissues than in the
adjacent normal mucosae, and a significant correlation
was found between the expression of HOXA1 and cyclin
D1. Second, knockdown of HOXA1 expression in GC
cells not only inhibited cell proliferation, migration, and
invasion and induced changes in the cell cycle in vitro
but also suppressed xenograft tumor formation. More-
over, HOXA1 knockdown in GC cells decreased cyclin
D1 expression. Third, our clinical data showed that
HOXA1, alone or in combination with cyclin D1, may
serve as a novel prognostic biomarker for GC. Future
studies will focus on the mechanism underlying the role
of HOXA1 in the progression of GC and the potential
for targeting HOXA1 in GC treatment.
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